Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 54Other hematologic neoplasm 44Sarcoma 14Myeloid 13CNS 11Genitourinary 7Plasma cell 5Gastrointestinal 5Dermatologic 5Breast 5Other solid neoplasm 4Thoracic 2Gynecologic 2Classical hematology 2

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Mesna × Thoracic × Clear all
NCT01752517 2012-12-19

Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer

Peking Union Medical College Hospital

Unknown
60 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01749072 2012-12-13

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Peking Union Medical College Hospital

Phase 2 Unknown
120 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡